These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 7491387)

  • 1. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia.
    Pollock BG; Mulsant BH; Sweet RA; Rosen J; Altieri LP; Perel JM
    Psychopharmacol Bull; 1995; 31(2):327-31. PubMed ID: 7491387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol.
    Jerling M; Dahl ML; Aberg-Wistedt A; Liljenberg B; Landell NE; Bertilsson L; Sjöqvist F
    Clin Pharmacol Ther; 1996 Apr; 59(4):423-8. PubMed ID: 8612387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics in Alzheimer's disease.
    Cacabelos R
    Methods Mol Biol; 2008; 448():213-357. PubMed ID: 18370236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased frequency of cytochrome P450 2D6 poor metabolizers among patients with metoprolol-associated adverse effects.
    Wuttke H; Rau T; Heide R; Bergmann K; Böhm M; Weil J; Werner D; Eschenhagen T
    Clin Pharmacol Ther; 2002 Oct; 72(4):429-37. PubMed ID: 12386645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychotropic medications and cytochrome P450 2D6: pharmacokinetic considerations in the elderly.
    Shulman RW; Ozdemir V
    Can J Psychiatry; 1997 Jun; 42 Suppl 1():4S-9S. PubMed ID: 9220124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Usage of drugs with potential adverse effects on cognition in a memory-clinic].
    Weih M; Scholz S; Reiss K; Alexopoulos P; Degirmenci U; Richter-Schmidinger T; Kornhuber J
    Fortschr Neurol Psychiatr; 2009 Sep; 77(9):523-7. PubMed ID: 19644785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
    Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
    Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Extrapyramidal side effects of neuroleptic and antidepressant treatment: assessment of potential risk factors through CYP2D6 genetic polymorphism].
    Reggiani K; Vandel P; Haffen E; Sechter D; Bizouard P; Vandel S
    Encephale; 2000; 26(1):62-7. PubMed ID: 10875063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP2D6 genotype on adverse effects during treatment with metoprolol: a prospective clinical study.
    Fux R; Mörike K; Pröhmer AM; Delabar U; Schwab M; Schaeffeler E; Lorenz G; Gleiter CH; Eichelbaum M; Kivistö KT
    Clin Pharmacol Ther; 2005 Oct; 78(4):378-87. PubMed ID: 16198657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
    Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
    J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias.
    Aarsland D; Perry R; Larsen JP; McKeith IG; O'Brien JT; Perry EK; Burn D; Ballard CG
    J Clin Psychiatry; 2005 May; 66(5):633-7. PubMed ID: 15889951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism.
    Linnet K; Wiborg O
    Clin Pharmacol Ther; 1996 Jul; 60(1):41-7. PubMed ID: 8689810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trials.
    Katz I; de Deyn PP; Mintzer J; Greenspan A; Zhu Y; Brodaty H
    Int J Geriatr Psychiatry; 2007 May; 22(5):475-84. PubMed ID: 17471598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacogenetic study of the response to flecainide and propafenone in patients with atrial fibrillation].
    Martínez-Sellés M; Castillo I; Montenegro P; Martín ML; Almendral J; Sanjurjo M
    Rev Esp Cardiol; 2005 Jun; 58(6):745-8. PubMed ID: 15970126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study.
    Rau T; Wohlleben G; Wuttke H; Thuerauf N; Lunkenheimer J; Lanczik M; Eschenhagen T
    Clin Pharmacol Ther; 2004 May; 75(5):386-93. PubMed ID: 15116051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolism-based drug-drug interactions: what determines individual variability in cytochrome P450 induction?
    Tang C; Lin JH; Lu AY
    Drug Metab Dispos; 2005 May; 33(5):603-13. PubMed ID: 15673596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tramadol as a new probe for cytochrome P450 2D6 phenotyping: a population study.
    Pedersen RS; Damkier P; Brosen K
    Clin Pharmacol Ther; 2005 Jun; 77(6):458-67. PubMed ID: 15961977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.
    Zineh I; Beitelshees AL; Gaedigk A; Walker JR; Pauly DF; Eberst K; Leeder JS; Phillips MS; Gelfand CA; Johnson JA
    Clin Pharmacol Ther; 2004 Dec; 76(6):536-44. PubMed ID: 15592325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.